Treatment of dry eye syndrome with orally administered CF101: Data from a phase 2 clinical trial

Ophthalmology

Volumn 117, Issue 7, 2010, Pages 1287-1293

  Avni, Isaac ^a   Garzozi, Hanna J ^b   Barequet, Irina S ^c   Segev, Fanni ^d   Varssano, David ^e   Sartani, Gil ^f   Chetrit, Noa ^a   Bakshi, Erez ^a   Zadok, David ^a   Tomkins, Oren ^b   Litvin, Gilad ^d   Jacobson, Kenneth A ^g   Fishman, Sari ^h   Harpaz, Zivit ^h   Farbstein, Motti ^h   Yehuda, Sara Bar ^h   Silverman, Michael H ^h   Kerns, William D ^h   Bristol, David R ^h   Cohn, Ilan ^h   Fishman, Pnina ^h   more..

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d MEIR MEDICAL CENTER   (Israel)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f HAEMEK MEDICAL CENTER   (Israel)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^h Can Fite BioPharma Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA LESION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY EYE; EYE EXAMINATION; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; STAINING; TREATMENT RESPONSE; VITAL SIGN; XEROSTOMIA;

ADENOSINE; ADMINISTRATION, ORAL; CORNEA; DOUBLE-BLIND METHOD; DRY EYE SYNDROMES; ELECTROCARDIOGRAPHY; FEMALE; FLUOROPHOTOMETRY; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; RECEPTOR, ADENOSINE A3; TEARS; TREATMENT OUTCOME;

EID: 77954348601     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.11.029     Document Type: Article

References (34)

1. R. Latkany Dry eyes: etiology and management Curr Opin Ophthalmol 19 2008 287 291
2. R.I. Fox, M. Stern, and P. Michelson Update in Sjgren's syndrome Curr Opin Rheumatol 12 2000 391 398
3. The definition and classification of dry eye disease report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007) Ocul Surf 5 2007 75 92
4. L. Luo, D.Q. Li, and A. Doshi Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface Invest Ophthalmol Vis Sci 4 2004 4293 4301
5. A. Acera, G. Rocha, and E. Vecino Inflammatory markers in the tears of patients with ocular surface disease Ophthalmic Res 40 2008 315 321
6. S.C. Pflugfelder, W. Farley, and L. Luo Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye Am J Pathol 166 2005 61 71
7. K.C. Yoon, C.S. De Paiva, and H. Qi Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress Invest Ophthalmol Vis Sci 48 2007 2561 2569
8. K. Tsubota, K. Fukagawa, and T. Fujihara Regulation of human leukocyte antigen expression in human conjunctival epithelium Invest Ophthalmol Vis Sci 40 1999 28 34
9. P.J. Pisella, F. Brignole, and C. Debbasch Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca Ophthalmology 107 2000 1841 1849
10. C.S. de Paiva, and S.C. Pflugfelder Rationale for anti-inflammatory therapy in dry eye syndrome Arq Bras Oftalmol 71 suppl 2008 89 95
11. A. Peral, C.O. Domnguez-Godnez, G. Carracedo, and J. Pintor Therapeutic targets in dry eye syndrome Drug News Perspect 21 2008 166 176
12. E. Donnenfeld, and S.C. Pflugfelder Topical ophthalmic cyclosporine: pharmacology and clinical uses Surv Ophthalmol 54 2009 321 338
13. J. Pintor, A. Peral, and C.H. Hoyle Effects of diadenosine polyphosphates on tear secretion in New Zealand white rabbits J Pharmacol Exp Ther 300 2002 291 297
14. J. Tauber, W.F. Davitt, and J.E. Bokosky Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye Cornea 23 2004 784 792
15. G.L. Stiles Adenosine receptors and beyond: molecular mechanisms of physiological regulation Clin Res 38 1990 10 18
16. E. Baharav, S. Bar-Yehuda, and L. Madi Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models J Rheumatol 32 2005 469 476
17. P. Fishman, S. Bar-Yehuda, and L. Madi The PI3KNF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis [article online] Arthritis Res Ther 8 2006 R33 http://arthritis-research.com/content/8/1/R33 Accessed November 8, 2009
18. L. Rath-Wolfson, S. Bar Yehuda, and L. Madi IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis Clin Exp Rheumatol 24 2006 400 406
19. S. Bar-Yehuda, M.H. Silverman, and W.D. Kerns The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis Expert Opin Investig Drugs 16 2007 1601 1613
20. J. Mabley, F. Soriano, and P. Pacher The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis Eur J Pharmacol 466 2003 323 329
21. S. Bar-Yehuda, L. Rath-Wolfson, and L. Del Valle Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment Arthritis Rheum 60 2009 3061 3071
22. H.T. Lee, M. Kim, and J.D. Joo A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis Am J Physiol Regul Integr Comp Physiol 291 2006 R959 R969
23. A.R. van Troostenburg, E.V. Clark, and W.D. Carey Tolerability, pharmacokinetics, and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men Int J Clin Pharmacol Ther 42 2004 534 542
24. M.H. Silverman, V. Strand, and D. Markovits Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial J Rheumatol 35 2008 41 48
25. R.M. Schiffman, M.D. Christianson, and G. Jacobsen Reliability and validity of the Ocular Surface Disease Index Arch Ophthalmol 118 2000 615 621
26. I.J. Cohen Use of fluorescein in eye injuries J Occup Med 5 1963 540 541
27. M.C. Holland Fluorescein staining of the cornea JAMA 188 1964 81
28. D. Kellerman, A. Rossi Mospan, and J. Engels Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3 Pulm Pharmacol Ther 21 2008 600 607
29. D.A. Carr, C.H. Mitchell, and K. Peterson-Yantorno Similarity of A(3)-adenosine and swelling-activated Cl() channels in nonpigmented ciliary epithelial cells Am J Physiol Cell Physiol 279 2000 C440 C451
30. H. Yang, M.Y. Avila, and K. Peterson-Yantorno The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure Curr Eye Res 30 2005 747 754
31. C.W. Do, and M.M. Civan Swelling-activated chloride channels in aqueous humour formation: on the one side and the other Acta Physiol (Oxf) 187 2006 345 352
32. H. Liu, C.G. Begley, and M. Chen A link between tear instability and hyperosmolarity in dry eye Invest Ophthalmol Vis Sci 50 2009 3671 3679
33. A.C. Yeo, A. Carkeet, L.G. Carney, and M.K. Yap Relationship between goblet cell density and tear function tests Ophthalmic Physiol Opt 23 2003 87 94
34. K. Sall, O.D. Stevenson, T.K. Mundorf, B.L. Reis CsA Phase 3 Study Group Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease Ophthalmology 107 2000 631 639